These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 38297316)

  • 1. BORIS/CTCFL epigenetically reprograms clustered CTCF binding sites into alternative transcriptional start sites.
    Pugacheva EM; Bhatt DN; Rivero-Hinojosa S; Tajmul M; Fedida L; Price E; Ji Y; Loukinov D; Strunnikov AV; Ren B; Lobanenkov VV
    Genome Biol; 2024 Jan; 25(1):40. PubMed ID: 38297316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testis-specific transcriptional regulators selectively occupy BORIS-bound CTCF target regions in mouse male germ cells.
    Rivero-Hinojosa S; Kang S; Lobanenkov VV; Zentner GE
    Sci Rep; 2017 Feb; 7():41279. PubMed ID: 28145452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
    Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV
    Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovering a binary CTCF code with a little help from BORIS.
    Lobanenkov VV; Zentner GE
    Nucleus; 2018 Jan; 9(1):33-41. PubMed ID: 29077515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choice of binding sites for CTCFL compared to CTCF is driven by chromatin and by sequence preference.
    Bergmaier P; Weth O; Dienstbach S; Boettger T; Galjart N; Mernberger M; Bartkuhn M; Renkawitz R
    Nucleic Acids Res; 2018 Aug; 46(14):7097-7107. PubMed ID: 29860503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analyses of CTCF and BORIS occupancies uncover two distinct classes of CTCF binding genomic regions.
    Pugacheva EM; Rivero-Hinojosa S; Espinoza CA; Méndez-Catalá CF; Kang S; Suzuki T; Kosaka-Suzuki N; Robinson S; Nagarajan V; Ye Z; Boukaba A; Rasko JE; Strunnikov AV; Loukinov D; Ren B; Lobanenkov VV
    Genome Biol; 2015 Aug; 16(1):161. PubMed ID: 26268681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the relative and combined contribution of CTCF and CTCFL to genomic regulation.
    Nishana M; Ha C; Rodriguez-Hernaez J; Ranjbaran A; Chio E; Nora EP; Badri SB; Kloetgen A; Bruneau BG; Tsirigos A; Skok JA
    Genome Biol; 2020 May; 21(1):108. PubMed ID: 32393311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors.
    Renaud S; Pugacheva EM; Delgado MD; Braunschweig R; Abdullaev Z; Loukinov D; Benhattar J; Lobanenkov V
    Nucleic Acids Res; 2007; 35(21):7372-88. PubMed ID: 17962299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combined action of CTCF and its testis-specific paralog BORIS is essential for spermatogenesis.
    Rivero-Hinojosa S; Pugacheva EM; Kang S; Méndez-Catalá CF; Kovalchuk AL; Strunnikov AV; Loukinov D; Lee JT; Lobanenkov VV
    Nat Commun; 2021 Jun; 12(1):3846. PubMed ID: 34158481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
    Hoivik EA; Kusonmano K; Halle MK; Berg A; Wik E; Werner HM; Petersen K; Oyan AM; Kalland KH; Krakstad C; Trovik J; Widschwendter M; Salvesen HB
    Oncotarget; 2014 Feb; 5(4):1052-61. PubMed ID: 24658009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cancer-associated CTCFL/BORIS protein targets multiple classes of genomic repeats, with a distinct binding and functional preference for humanoid-specific SVA transposable elements.
    Pugacheva EM; Teplyakov E; Wu Q; Li J; Chen C; Meng C; Liu J; Robinson S; Loukinov D; Boukaba A; Hutchins AP; Lobanenkov V; Strunnikov A
    Epigenetics Chromatin; 2016; 9(1):35. PubMed ID: 27588042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer.
    Klenova EM; Morse HC; Ohlsson R; Lobanenkov VV
    Semin Cancer Biol; 2002 Oct; 12(5):399-414. PubMed ID: 12191639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The male germ cell gene regulator CTCFL is functionally different from CTCF and binds CTCF-like consensus sites in a nucleosome composition-dependent manner.
    Sleutels F; Soochit W; Bartkuhn M; Heath H; Dienstbach S; Bergmaier P; Franke V; Rosa-Garrido M; van de Nobelen S; Caesar L; van der Reijden M; Bryne JC; van Ijcken W; Grootegoed JA; Delgado MD; Lenhard B; Renkawitz R; Grosveld F; Galjart N
    Epigenetics Chromatin; 2012 Jun; 5(1):8. PubMed ID: 22709888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
    Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS
    Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTCF and CTCFL in cancer.
    Debaugny RE; Skok JA
    Curr Opin Genet Dev; 2020 Apr; 61():44-52. PubMed ID: 32334335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells.
    Debruyne DN; Dries R; Sengupta S; Seruggia D; Gao Y; Sharma B; Huang H; Moreau L; McLane M; Day DS; Marco E; Chen T; Gray NS; Wong KK; Orkin SH; Yuan GC; Young RA; George RE
    Nature; 2019 Aug; 572(7771):676-680. PubMed ID: 31391581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolution of epigenetic regulators CTCF and BORIS/CTCFL in amniotes.
    Hore TA; Deakin JE; Marshall Graves JA
    PLoS Genet; 2008 Aug; 4(8):e1000169. PubMed ID: 18769711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Diverging Routes of BORIS and CTCF: An Interactomic and Phylogenomic Analysis.
    Jabbari K; Heger P; Sharma R; Wiehe T
    Life (Basel); 2018 Jan; 8(1):. PubMed ID: 29385718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Widespread expression of BORIS/CTCFL in normal and cancer cells.
    Jones TA; Ogunkolade BW; Szary J; Aarum J; Mumin MA; Patel S; Pieri CA; Sheer D
    PLoS One; 2011; 6(7):e22399. PubMed ID: 21811597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CTCF mediates chromatin looping via N-terminal domain-dependent cohesin retention.
    Pugacheva EM; Kubo N; Loukinov D; Tajmul M; Kang S; Kovalchuk AL; Strunnikov AV; Zentner GE; Ren B; Lobanenkov VV
    Proc Natl Acad Sci U S A; 2020 Jan; 117(4):2020-2031. PubMed ID: 31937660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.